April 17, 2015
BioTissue Hosts Educational Events on Advances in theTreatment of Dry Eye and Lid Margin Disease at ASCRS
Innovative products facilitate quality healing on the ocular surface
MIAMI, Fla., April 17, 2015 – BioTissue®, Inc., the industry leader in regenerative tissue therapies and ocular hygiene products for lid margin and ocular surface diseases, will host key educational events and training sessions highlighting advances in the treatment of dry eye and lid margin diseases at this year’s ASCRS 2015 taking place April 17-21, 2015 in San Diego. BioTissue’s range of products facilitate quality healing on the ocular surface allowing patients to heal faster with improved clinical outcomes.
BioTissue will host a Dry Eye Center of Excellence Instructional Course to provide an overview of a proven approach to implement its PROKERA® biologic corneal bandage for the treatment of Dry Eye Workshop (DEWS) level 3 and 4 patients with corneal involvement. Presenters Brandon D. Ayres, MD, Wills Eye Institute and Nick Pisani, Director of Clinical Implementation, BioTissue will discuss patient selection, workflow protocol, and practice management. They will also review study data on PROKERA® for Dry Eye and provide guidance on implementation, enhancing the patient experience and improved practice revenue. The event will be held on Saturday, April 19 from 6:30pm – 8:30 pm at the Marriott Marquis.
“Treating patients with chronic Dry Eye can be challenging particularly for those patients with more severe cases with corneal involvement,” said Brandon Ayres, MD. “PROKERA® is an innovative treatment that reduces inflammation and promotes healing, providing patients with improved clinical outcomes, reduced recovery times, and improved visual acuity. My patients are pleased and benefit from an improved quality of life.”
BioTissue will also host a Meet the Experts – Prokera® Case Study Series in its booth #1717 on Saturday, April 18 and Sunday, April 19. Speakers will include Neel Desai, MD, The Eye Institute of West Florida; Scheffer Tseng, MD, The Ocular Surface Center; Gary Wortz, MD, Commonwealth Eye Surgery, Preeya Gupta, MD, Duke Eye Center, and Brandon Ayres, MD, Wills Eye Institute. Additionally, BioTissue is hosting an Ad Board Meeting with leading cataract surgeons to discuss preparing the ocular surface prior to cataract surgery to provide improved outcomes on challenging OSD patients.
BioTissue, Inc., a subsidiary of TissueTech, is a privately held ophthalmic biotechnology company that develops innovative wound healing and hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. BioTissue provides a comprehensive line of cryopreserved amniotic membrane ocular wound healing products, including AmnioGraft®, a biologic ocular transplantation graft; AmnioGuard®, a biologic glaucoma shunt tube graft; and the PROKERA® family of biologic corneal bandage devices. These products incorporate human amniotic membrane processed with the Company’s proprietary CryoTek® method proven to preserve the biological properties of amniotic membrane and umbilical cord tissue essential for anti-inflammatory and anti-scarring effects compared with the dehydration method that drastically alters the structural and biological integrity of this tissue.1 BioTissue also developed and markets the Cliradex® line of products, a natural lid, lash and facial cleanser with 4-Terpineol, the active component of tea tree oil (TTO), for the management of symptoms in ocular diseases such as blepharitis, demodex, and rosacea. For more information, visit www.biotissue.com